In line with the genetic approaches, treatment with CBPD-409 resulted in stronger cytotoxicity in all tested AR-positive prostate cancer cell lines relative to GNE-049 (Fig. 5b and Extended Data Fig. 8a,b). The gene discussed is AR; the disease is Familial prostate cancer.